LALPATHLAB2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2020-04-012020-06-30in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2020-04-01 2021-03-31 2020-07-24 INR Millions First quarter Single segment the business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2020-04-01 2020-06-30 Unaudited Consolidated 2660000000.00 114000000.00 2774000000.00 759000000.00 0.00 0.00 595000000.00 37000000.00 179000000.00 823000000.00 2393000000.00 381000000.00 0.00 381000000.00 121000000.00 -24000000.00 97000000.00 0.00 284000000.00 0.00 0.00 0.00 0.00 284000000.00 -9000000.00 275000000.00 284000000.00 0.00 275000000.00 0.00 833000000.00 10 3.45 3.44 0.00 0.00 3.45 3.44 1.tThe above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 July, 2020 respectively. n2.tThe above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). n3.tThese financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. n4.tFigures for the quarter ended 31 March, 2020 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2019, which were subjected to limited review. n5.tThe Board of Directors of the Parent Company and one of the subsidiary company's 'APL Institute of Clinical Laboratory & Research Private Limited' ( APL ), in their respective meetings held on 3 February, 2020 have approved the “Scheme of Amalgamation” of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Parent Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals. n6.tThe Board of Directors of the Group, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. n7.tThe Group has taken into account the possible impacts of COVID-19 in preparation of the interim consolidated financial results, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has considered internal and certain external sources of information including credit reports, economic forecasts and industry reports upto the date of approval of the consolidated financial results and expects to recover the carrying amount of its assets. The impact of COVID-19 on the consolidated financial results may differ from that estimated as at the date of approval of the interim consolidated financial results. Such changes, if any, will be prospectively recognised. The Group will continue to closely monitor any material changes to future economic conditions. Fees to collection centers/channel partners 293000000.00 Other expenses 530000000.00